Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | MLYCD | O95822 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394361 | 0.91 | HPGD (0.72) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL4491643 | 0.87 | TDP1 (0.75) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL1901528 | 0.85 | TDP1 (0.68) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL95374 | 0.85 | TDP1 (0.73) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL2422719 | 0.85 | TDP1 (0.73) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL13212973 | 0.85 | TDP1 (0.73) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL6023593 | 0.85 | TDP1 (1.00) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL18905578 | 0.83 | RAB9A (0.64) | HPGDALDH1A1LMNATDP1POLB | |
| SCHEMBL4672305 | 0.83 | TDP1 (0.69) | HPGDALDH1A1LMNATDP1TP53 | |
| SCHEMBL8404655 | 0.83 | TDP1 (0.74) | HPGDALDH1A1LMNATDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | claimed |
| EP-1928879-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | Brystol-Myers Squibb Company (US) | 2008-06-11 | — | — | EP | claimed |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | CELGENE CORPORATION | 2008-03-13 | — | — | US | claimed |
| WO-2007136640-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE | CELGENE CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | claimed |
| JP-2076841-A | — | — | None | — | — | JP | disclosed |
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023202583-A1 | FXR REGULATOR AND USE THEREOF | 北京大学 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903559-A | FXR modulators and uses thereof | 北京大学 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023034413-A2 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| CN-115397806-A | Aryl and heteroaryl compounds and their therapeutic use in conditions associated with altered activity of galactocerebrosidase | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| CN-101848899-A | N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators | ORGANON NV | 2010-09-29 | — | — | CN | disclosed |
| WO-2008039007-A1 | INDOL DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-04-03 | — | — | WO | disclosed |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | CELGENE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| WO-2007136640-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE | CELGENE CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| JP-H0276841-A | PRODUCTION OF AMINOLEVULINIC ACIDS | OSAKA ORGANIC CHEM IND LTD | 1990-03-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GBA1, GALC, MAN2B1 | HPGD 3402/4885ALDH1A1 386/4885LMNA 427/4885 |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | TNF, DHPS, IDO1 | HPGD 175/4885ALDH1A1 230/4885LMNA 2059/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | HPGD 449/4885ALDH1A1 1178/4885LMNA 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.